CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Slides:

Advertisements

Similar presentations

Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients Michel Ovize Cardiology Hospital and Inserm U886 Lyon.

Advertisements

Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.

Randomized, double-blind, multicenter, controlled trial.

Effects of PG , a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction Effects of PG ,

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

A Randomized, Double-blind, Placebo-controlled Trial of Intravenous Erythropoietin in Patients with ST-Segment Elevation Myocardial Infarction – Primary.

(p for noninferiority = 0.01)

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

CARIN Trial design: Patients undergoing coronary angiography were randomized in a 1:1:1:1 fashion to CMX mg/kg, 3.6 mg/kg, 4.8 mg/kg, or placebo.

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

Valsartan in Acute Myocardial Infarction Trial Investigators

1224 STEMI pts, no reperfusion, < 24 hours from onset

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

(p < for group 1 or 2 vs. group 3)

IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus.

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.

Angiography-guided PCI

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Primary endpoint at 1 year

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

EXCEL Trial design: Patients with unprotected left main disease were randomized to either PCI with an Xience everolimus-eluting stent (EES) or CABG. They.

MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those

OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

ALPS Trial design: Patients with adult nontraumatic out-of-hospital cardiac arrest (OOHCA) and persistent or recurrent VT/VF after ≥1 shock were randomized.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.

Nat. Rev. Cardiol. doi: /nrcardio

AMISTAD II: Study Design

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

EXPLORE Trial design: Patients with STEMI treated with primary PCI and with evidence of noninfarct artery chronic total occlusion (CTO) were randomized.

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p = 0.32 for noninferiority)

AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.

(p < for noninferiority)

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

IMPRESSION Trial design: Patients presenting with acute MI and undergoing an invasive approach, along with ticagrelor loading dose, were randomized to.

(p for noninferiority < 0.001)

(p = for noninferiority)

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Ischemic Postconditioning

TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)

Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Primary safety endpoint

MOMENTUM 3 Trial design: Patients with advanced heart failure were randomized to a centrifugal-flow pump (n = 152) vs. an axial-flow pump (n = 142). Results.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

(p for noninferiority = 0.01)

MATRIX: Radial vs. Femoral

MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

Presentation transcript:

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary reperfusion. (p = 0.77) Results All-cause death, worsening heart failure during the index hospitalization, rehospitalization for heart failure, or adverse LV remodeling within 1 year: 59.0% of the cyclosporine group vs. 58.1% of the placebo group (p = 0.77) 59.0 58.1 % Conclusions Among patients with anterior STEMI undergoing primary PCI, IV cyclosporine failed to improve clinical outcomes or prevent adverse LV remodeling Cyclosporine Placebo Cung TT, et al. N Engl J Med 2015;373:1021-31